For many neuroendocrine tumour (NET) patients, there comes a moment in the treatment journey when the oncologist says something like: “Let’s see if you are a candidate for PRRT.” And immediately, two questions arise — what exactly is PRRT, and how is eligibility for it decided?
Here is the short version that surprises most families: PRRT eligibility is not decided by a blood test, and not by a biopsy alone. The gateway is an imaging study — a somatostatin receptor PET scan such as the 68Ga DOTANOC or NOTANOC PET CT. What that scan shows about your tumour’s receptors largely determines whether Lu-177 based therapy is even on the table. This guide explains the whole eligibility picture in plain language: what PRRT is, what the scan must demonstrate, why a second FDG scan is sometimes added, and what the complete work-up looks like — so you walk into your oncologist’s discussion already understanding the map.
Quick answer: PRRT (Peptide Receptor Radionuclide Therapy, usually Lu-177 based) works only when tumour cells carry enough somatostatin receptors to absorb the therapeutic dose. A 68Ga DOTANOC or NOTANOC PET CT scan is the standard test that demonstrates this: if your tumour deposits show strong tracer uptake — typically brighter than the normal liver background — receptor expression is considered adequate for PRRT to be considered. Final eligibility is then decided by your treating team after checking disease grade, progression status, kidney function, and blood counts. The receptor scan work-up is available daily at Neurad Diagnostic & Healthcare LLP, Paschim Vihar, Delhi — call +91 8368225620.
What Is PRRT, in Plain Language?
PRRT stands for Peptide Receptor Radionuclide Therapy. Think of it as the therapeutic twin of your DOTANOC scan:
- In the diagnostic scan, a somatostatin-like peptide carries a small imaging isotope (Gallium-68) to receptor-positive tumour cells — so we can see them.
- In PRRT, the very similar peptide carries a therapeutic isotope — most commonly Lutetium-177 (Lu-177) — to those same receptor-positive cells, delivering targeted radiation to the tumour from the inside while largely sparing normal tissue.
This “see it, then treat it” pairing is called theranostics — and it explains the central eligibility rule: if the diagnostic tracer does not bind strongly to your tumour, the therapeutic dose will not either. The scan is a dress rehearsal for the treatment. PRRT is an established option, supported by randomised trial evidence in progressive midgut NETs, and is typically considered for well-differentiated, somatostatin receptor-positive tumours that are progressing despite somatostatin analogue therapy.
Why the DOTANOC / NOTANOC Scan Is the Gateway Test
Somatostatin receptor PET — whether performed as a 68Ga DOTANOC PET CT or its chemically-sibling study, the 68Ga NOTANOC PET CT — maps two things at once:
- Where the disease is — primary site, lymph nodes, liver, bones, anywhere in the body, in one whole-body acquisition.
- How strongly each deposit expresses somatostatin receptors — measured visually against normal organs and semi-quantitatively through SUV values.
For PRRT purposes, the second part is the decision-maker. Nuclear medicine physicians grade lesion uptake against reference organs — a concept clinicians know as the Krenning score. In everyday language: tumour deposits should light up clearly brighter than the normal liver (ideally approaching or exceeding spleen-level brightness) for PRRT to be expected to deliver a meaningful therapeutic dose. Faint uptake at or below liver background suggests the receptors are too sparse for the treatment to work well.
One nuance an experienced reader will handle for you: some organs — spleen, kidneys, liver, pituitary, uncinate pancreas — show normal physiological uptake. That is expected biology, not disease, and it is one of the reasons receptor PET reads best in qualified nuclear medicine hands.
The “Flip-Flop” Problem — Why an FDG PET Is Sometimes Added
Here is the part of the eligibility picture that patients rarely hear explained. Neuroendocrine tumours exist on a spectrum:
- Well-differentiated, slower-growing NETs usually keep their somatostatin receptors → bright on DOTANOC/NOTANOC, often quiet on FDG. These are the classic PRRT candidates.
- Poorly differentiated or transforming disease tends to lose receptors and switch to high glucose metabolism → quiet on DOTANOC, bright on FDG. This pattern responds poorly to PRRT and usually points toward chemotherapy-based strategies instead.
Because a single patient can harbour both kinds of deposits at once, oncologists sometimes order the receptor scan and an FDG PET together — the so-called flip-flop assessment. If any significant lesion is FDG-positive but receptor-negative, the treating team knows PRRT alone will not control that lesion, and the plan changes accordingly. Both studies are performed at Neurad Diagnostic, and when your doctor orders the pair, we schedule them in coordination so the combined picture reaches your oncologist quickly.
Who Is Typically Considered for PRRT?
Final eligibility always rests with your treating oncology/nuclear medicine therapy team — but the profile they generally look for includes:
- Confirmed neuroendocrine tumour, usually well-differentiated (commonly Grade 1 or Grade 2 on biopsy, judged by the Ki-67 index)
- Strong somatostatin receptor expression across disease sites on DOTANOC/NOTANOC PET, as described above
- Disease that is progressing or symptomatic despite somatostatin analogue therapy, or otherwise judged by the team to warrant escalation
- Adequate organ reserve — kidney function and bone-marrow counts matter, because Lu-177 clears through the kidneys and mildly affects marrow
- Reasonable overall fitness (performance status) to benefit from a multi-cycle treatment course
Notice how the list works: the biopsy establishes what the tumour is, the receptor scan establishes whether the target exists, and the lab and fitness checks establish whether the body can receive the treatment safely. All three legs matter; the scan is simply the one that opens or closes the PRRT door first.
The Step-by-Step PRRT Eligibility Work-Up
Step 1 — Baseline receptor mapping. A whole-body 68Ga DOTANOC or NOTANOC PET CT documents every disease site and its receptor intensity. If you are on long-acting somatostatin analogue therapy, the scan is timed relative to your injection cycle — our scheduling team coordinates this with your treating doctor, so do not stop any medication on your own.
Step 2 — FDG PET where indicated. If your doctor wants the flip-flop assessment — common in Grade 2 disease, rising markers, or unusually fast progression — the FDG study is added, ideally within a short window of the receptor scan so the comparison is fair.
Step 3 — Reporting built for the referral. A PRRT-oriented report does more than list lesions: it grades uptake against liver and spleen references, provides SUV values for representative lesions, flags any receptor-negative/FDG-positive sites, and compares against prior imaging. At Neurad Diagnostic, receptor studies are reported within 24 hours by our nuclear medicine physicians — Dr. Swagat Dash (MBBS, DNB – Nuclear Medicine) and Dr. Pradeep Chaurasiya (MBBS, DNB – Nuclear Medicine) — in a format your PRRT centre can act on directly.
Step 4 — The therapy team’s decision. With imaging in hand, the treating team reviews grade, progression history, kidney and marrow labs, and overall fitness, and decides on PRRT, continued analogue therapy, chemotherapy, targeted therapy, or a combination. If PRRT proceeds, the same receptor scan later becomes the yardstick for measuring treatment response.
Step 5 — Follow-up imaging. After PRRT cycles, periodic receptor PET tracks how deposits are responding — one more reason the baseline study is worth doing well the first time.
Where Neurad Diagnostic Fits in Your PRRT Journey
Neurad Diagnostic is a dedicated nuclear medicine diagnostic centre — we perform the imaging work-up on which PRRT decisions rest, working alongside your treating oncologist and therapy centre. Three things matter practically for NET families here:
- Daily tracer availability. Gallium-68 cannot be stockpiled — its 68-minute half-life means the tracer must be produced near your injection time. Our in-house 68Ga Gallium Generator programme supports daily DOTANOC/NOTANOC scheduling, so an eligibility work-up does not wait weeks for a tracer supply day.
- Both halves of the flip-flop under one roof. Receptor PET and FDG PET can be coordinated at one centre, on one imaging platform, with one comparative reporting team.
- Reports written for decisions, not just description. Uptake grading, SUV values, and prior-study comparison — the specific details a PRRT referral needs — delivered within 24 hours.
For cost-related questions on the receptor study itself, our honest breakdown of the DOTANOC PET scan cost in Delhi covers the factors, checklist, and insurance guidance. And for safety questions — radiation, precautions at home, scanning while on medication — see our plain-language guide to PET scan side effects and precautions.
Frequently Asked Questions About PRRT Eligibility and the DOTANOC Scan
1. Can I get PRRT without a DOTANOC or NOTANOC scan?
No responsible therapy team offers PRRT without documented somatostatin receptor imaging — the scan is the evidence that the treatment has a target to bind to. It is the standard, expected gateway test.
2. My DOTANOC scan showed “strong uptake.” Does that mean I will definitely get PRRT?
It means the imaging leg of eligibility looks favourable. The treating team still weighs tumour grade, progression status, kidney function, blood counts, and fitness before finalising. Strong uptake opens the door; the full picture decides.
3. What if my scan shows weak or absent uptake?
Weak receptor expression means PRRT is unlikely to deliver an effective dose, and your team will usually favour other strategies — chemotherapy, targeted agents, or locoregional treatments depending on your case. That is disappointing to hear, but discovering it on a scan is far better than discovering it after treatment.
4. Why did my doctor order an FDG PET too, when I already had a DOTANOC?
To check for the flip-flop pattern — deposits that have lost receptors and turned metabolically aggressive. FDG-positive, receptor-negative disease responds poorly to PRRT, and knowing about it changes the plan. The two scans answer different questions and together give the full map.
5. Do I need to stop my somatostatin analogue injection before the eligibility scan?
Do not stop anything on your own. The scan is typically timed relative to your long-acting injection cycle — often shortly before the next dose is due — and our scheduling team coordinates the date with your treating doctor.
6. What is a Krenning score, in simple terms?
It is the grading system nuclear medicine physicians use to describe how bright tumour uptake is compared with normal liver and spleen. Higher grades — uptake clearly brighter than liver — indicate receptor expression strong enough for PRRT to be considered effective.
7. Is PRRT itself performed at Neurad Diagnostic?
Neurad Diagnostic performs the complete imaging work-up — DOTANOC/NOTANOC and FDG PET CT — on which PRRT decisions are based, and provides reports structured for the therapy referral. The Lu-177 therapy itself is administered at licensed therapy facilities; your oncologist will direct that referral, and our imaging travels with you.
8. How often will the receptor scan be repeated if I undergo PRRT?
Your therapy team sets the schedule, but receptor PET is commonly repeated after treatment cycles to measure response and periodically thereafter for surveillance. Each follow-up is compared against your baseline — which is why the baseline study deserves to be done well.
9. Is the eligibility scan safe for someone already dealing with a NET diagnosis?
Yes. The Ga-68 tracer dose is tiny, has no drug-like effects, and its radioactivity decays within hours. The information it yields directly shapes major treatment decisions — a strongly favourable balance. Details in our PET scan safety guide.
10. How soon can I get the eligibility work-up done in Delhi?
With daily in-house tracer production at Neurad Diagnostic, DOTANOC/NOTANOC appointments are usually available within days, and reports follow within 24 hours. Call +91 8368225620 with your prescription and injection schedule, and the team will fix the optimal date.
Conclusion: The Scan That Opens the Door
PRRT is one of the most encouraging developments in neuroendocrine tumour care — targeted, evidence-backed, and increasingly accessible in India. But it is a receptor-targeted therapy, and receptors must be proven before they can be treated. That proof is exactly what the 68Ga DOTANOC or NOTANOC PET CT provides: a whole-body map of your disease and a receptor-by-receptor answer to the question your oncologist is really asking.
If PRRT has come up in your treatment discussions and you need the eligibility imaging done promptly and read expertly, call Neurad Diagnostic at +91 8368225620. Bring your prescription, your biopsy report, and your injection schedule — the team will handle the coordination from there.
Neurad Diagnostic & Healthcare LLP
B-3, opp. Metro Pillar No. 233, Near Paschim Vihar West Metro Station, New Multan Nagar, Paschim Vihar, New Delhi – 110056
Phone: +91 8368225620 | +91 7011968879
Website: https://neuraddiagnostic.com
About the Medical Team
Dr. Swagat Dash — MBBS, DNB (Nuclear Medicine & PET-CT Imaging)
Over a decade of clinical expertise in nuclear medicine and advanced diagnostic PET-CT imaging.
Dr. Pradeep Chaurasiya — MBBS, DNB (Nuclear Medicine, Molecular Imaging)
Several years of expertise in PET-CT scans and nuclear medicine procedures.
Dr. Nishant Thapar — MBBS, MD Radiology (High-End Diagnostic Imaging, MRI, CT)
Extensive experience in diagnostic imaging with advanced radiological equipment.
Practicing at Neurad Diagnostic & Healthcare LLP, B-3, Near Paschim Vihar West Metro Station, New Multan Nagar, Paschim Vihar, New Delhi — 110056.
Clinically reviewed by the nuclear medicine team at Neurad Diagnostic & Healthcare LLP. This content is for general information only and is not a substitute for advice from your treating doctor. PRRT eligibility is decided by your treating oncology and nuclear medicine therapy team based on your complete clinical picture — imaging findings are one essential component of that decision, not the whole of it.